Moberg Pharma Valuation
Is MBGP.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MBGP.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MBGP.F ($1.73) is trading below our estimate of fair value ($7.06)
Significantly Below Fair Value: MBGP.F is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MBGP.F?
Key metric: As MBGP.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is MBGP.F's PB Ratio? | |
|---|---|
| PB Ratio | 0.9x |
| Book | SEK 928.70m |
| Market Cap | SEK 873.63m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 64.7x |
| Enterprise Value/EBITDA | -23x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does MBGP.F's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
IKNA Ikena Oncology | 0.6x | 4.6% | US$82.5m |
LABP Landos Biopharma | 3.1x | -37.1% | US$71.7m |
VYNE VYNE Therapeutics | 0.7x | -18.2% | US$44.7m |
ORMP Oramed Pharmaceuticals | 0.6x | -163.0% | US$94.3m |
MBGP.F Moberg Pharma | 0.9x | 66.5% | US$873.6m |
Price-To-Book vs Peers: MBGP.F is good value based on its Price-To-Book Ratio (0.9x) compared to the peer average (1.3x).
Price to Book Ratio vs Industry
How does MBGP.F's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: MBGP.F is good value based on its Price-To-Book Ratio (0.9x) compared to the US Pharmaceuticals industry average (1.8x).
Price to Book Ratio vs Fair Ratio
What is MBGP.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate MBGP.F's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Spectrum Pharmaceuticals
US$209.9m
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
SPPI
US$1.03
7D
5.3%
1Y
17.0%
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$204.02
7D
6.8%
1Y
-3.2%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$58.64
7D
6.1%
1Y
14.8%